S&P 500   4,057.57 (+2.53%)
DOW   34,411.80 (+1.65%)
QQQ   290.96 (+3.70%)
AAPL   146.72 (+3.93%)
MSFT   251.38 (+4.60%)
META   117.44 (+7.29%)
GOOGL   99.86 (+4.91%)
AMZN   95.46 (+3.29%)
TSLA   190.00 (+5.07%)
NVDA   166.01 (+6.15%)
NIO   12.72 (+21.14%)
BABA   88.33 (+10.61%)
AMD   77.49 (+5.59%)
T   19.19 (+0.95%)
MU   57.01 (+3.43%)
CGC   3.58 (+4.68%)
F   13.87 (+0.87%)
GE   85.83 (+0.20%)
DIS   97.16 (+2.61%)
AMC   7.25 (-2.42%)
PYPL   78.56 (+1.18%)
PFE   49.71 (+0.44%)
NFLX   306.14 (+8.96%)
S&P 500   4,057.57 (+2.53%)
DOW   34,411.80 (+1.65%)
QQQ   290.96 (+3.70%)
AAPL   146.72 (+3.93%)
MSFT   251.38 (+4.60%)
META   117.44 (+7.29%)
GOOGL   99.86 (+4.91%)
AMZN   95.46 (+3.29%)
TSLA   190.00 (+5.07%)
NVDA   166.01 (+6.15%)
NIO   12.72 (+21.14%)
BABA   88.33 (+10.61%)
AMD   77.49 (+5.59%)
T   19.19 (+0.95%)
MU   57.01 (+3.43%)
CGC   3.58 (+4.68%)
F   13.87 (+0.87%)
GE   85.83 (+0.20%)
DIS   97.16 (+2.61%)
AMC   7.25 (-2.42%)
PYPL   78.56 (+1.18%)
PFE   49.71 (+0.44%)
NFLX   306.14 (+8.96%)
S&P 500   4,057.57 (+2.53%)
DOW   34,411.80 (+1.65%)
QQQ   290.96 (+3.70%)
AAPL   146.72 (+3.93%)
MSFT   251.38 (+4.60%)
META   117.44 (+7.29%)
GOOGL   99.86 (+4.91%)
AMZN   95.46 (+3.29%)
TSLA   190.00 (+5.07%)
NVDA   166.01 (+6.15%)
NIO   12.72 (+21.14%)
BABA   88.33 (+10.61%)
AMD   77.49 (+5.59%)
T   19.19 (+0.95%)
MU   57.01 (+3.43%)
CGC   3.58 (+4.68%)
F   13.87 (+0.87%)
GE   85.83 (+0.20%)
DIS   97.16 (+2.61%)
AMC   7.25 (-2.42%)
PYPL   78.56 (+1.18%)
PFE   49.71 (+0.44%)
NFLX   306.14 (+8.96%)
S&P 500   4,057.57 (+2.53%)
DOW   34,411.80 (+1.65%)
QQQ   290.96 (+3.70%)
AAPL   146.72 (+3.93%)
MSFT   251.38 (+4.60%)
META   117.44 (+7.29%)
GOOGL   99.86 (+4.91%)
AMZN   95.46 (+3.29%)
TSLA   190.00 (+5.07%)
NVDA   166.01 (+6.15%)
NIO   12.72 (+21.14%)
BABA   88.33 (+10.61%)
AMD   77.49 (+5.59%)
T   19.19 (+0.95%)
MU   57.01 (+3.43%)
CGC   3.58 (+4.68%)
F   13.87 (+0.87%)
GE   85.83 (+0.20%)
DIS   97.16 (+2.61%)
AMC   7.25 (-2.42%)
PYPL   78.56 (+1.18%)
PFE   49.71 (+0.44%)
NFLX   306.14 (+8.96%)
NASDAQ:ITCI

Intra-Cellular Therapies - ITCI Stock Forecast, Price & News

$53.89
+1.04 (+1.97%)
(As of 11/30/2022 03:22 PM ET)
Add
Compare
Today's Range
$51.52
$53.89
50-Day Range
$42.70
$52.88
52-Week Range
$34.43
$66.00
Volume
15,719 shs
Average Volume
699,048 shs
Market Capitalization
$5.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$67.50

Intra-Cellular Therapies MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
29.8% Upside
$67.50 Price Target
Short Interest
Healthy
3.36% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.23
Upright™ Environmental Score
News Sentiment
1.38mentions of Intra-Cellular Therapies in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$2.97 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.87) to ($1.79) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

166th out of 1,043 stocks

Pharmaceutical Preparations Industry

61st out of 510 stocks

ITCI stock logo

About Intra-Cellular Therapies (NASDAQ:ITCI) Stock

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

ITCI Stock News Headlines

Intra-Cellular Therapies Has My Attention
Is Intra-Cellular Therapies (ITCI) Stock a Worthy Buy?
ITCI Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies: What Lies Ahead
See More Headlines
Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

ITCI Company Calendar

Last Earnings
11/08/2021
Today
11/30/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/07/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ITCI
Employees
512
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$67.50
High Stock Price Forecast
$93.00
Low Stock Price Forecast
$49.00
Forecasted Upside/Downside
+25.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-284,130,000.00
Net Margins
-158.39%
Pretax Margin
-158.39%

Debt

Sales & Book Value

Annual Sales
$83.80 million
Book Value
$7.24 per share

Miscellaneous

Free Float
91,201,000
Market Cap
$5.10 billion
Optionable
Optionable
Beta
1.15

Key Executives

  • Dr. Sharon Mates Ph.D. (Age 69)
    Co-Founder, Chairman, CEO & Pres
    Comp: $2.25M
  • Mr. Lawrence J. Hineline CPA (Age 66)
    CPA, Sr. VP of Fin., CFO, Treasurer & Assistant Sec.
    Comp: $791.01k
  • Mr. Michael I. Halstead J.D. (Age 49)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $1.08M
  • Dr. Suresh K. Durgam M.D.Dr. Suresh K. Durgam M.D. (Age 53)
    Exec. VP & Chief Medical Officer
    Comp: $1.03M
  • Mr. Mark NeumannMr. Mark Neumann (Age 59)
    EVP & Chief Commercial Officer
    Comp: $1.01M
  • Dr. Robert E. Davis Ph.D. (Age 71)
    Sr. VP & Chief Scientific Officer
  • Mr. Juan Fernando Sanchez (Age 51)
    VP of Corp. Communications & Investor Relations
  • Ms. Karen Patruno Sheehy Esq. (Age 60)
    Sr. VP & Chief Compliance Officer
  • Dr. Michael Olchaskey
    Sr. VP & Head of Regulatory Affairs
  • Mr. John A. Bardi
    Sr. VP of Market Access, Policy & Gov. Affairs













ITCI Stock - Frequently Asked Questions

Should I buy or sell Intra-Cellular Therapies stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ITCI shares.
View ITCI analyst ratings
or view top-rated stocks.

What is Intra-Cellular Therapies' stock price forecast for 2023?

7 brokerages have issued 12 month price objectives for Intra-Cellular Therapies' stock. Their ITCI share price forecasts range from $49.00 to $93.00. On average, they predict the company's stock price to reach $67.50 in the next twelve months. This suggests a possible upside of 27.7% from the stock's current price.
View analysts price targets for ITCI
or view top-rated stocks among Wall Street analysts.

How have ITCI shares performed in 2022?

Intra-Cellular Therapies' stock was trading at $52.34 on January 1st, 2022. Since then, ITCI shares have increased by 1.0% and is now trading at $52.85.
View the best growth stocks for 2022 here
.

Are investors shorting Intra-Cellular Therapies?

Intra-Cellular Therapies saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 3,180,000 shares, a decrease of 21.7% from the October 31st total of 4,060,000 shares. Based on an average trading volume of 701,600 shares, the days-to-cover ratio is presently 4.5 days.
View Intra-Cellular Therapies' Short Interest
.

When is Intra-Cellular Therapies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our ITCI earnings forecast
.

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) released its quarterly earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by $0.03. The biopharmaceutical company had revenue of $22.21 million for the quarter, compared to the consensus estimate of $22.11 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 45.52% and a negative net margin of 158.39%. The firm's revenue was up 201.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.79) EPS.

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Who are Intra-Cellular Therapies' major shareholders?

Intra-Cellular Therapies' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.57%), BlackRock Inc. (7.50%), Bellevue Group AG (3.52%), Alliancebernstein L.P. (2.32%), Lord Abbett & CO. LLC (2.13%) and State Street Corp (2.09%). Insiders that own company stock include Andrew Satlin, Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Nostrand Robert L Van, Rory B Riggs, Sharon Mates and Suresh K Durgam.
View institutional ownership trends
.

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intra-Cellular Therapies' stock price today?

One share of ITCI stock can currently be purchased for approximately $52.85.

How much money does Intra-Cellular Therapies make?

Intra-Cellular Therapies (NASDAQ:ITCI) has a market capitalization of $5.01 billion and generates $83.80 million in revenue each year. The biopharmaceutical company earns $-284,130,000.00 in net income (profit) each year or ($3.32) on an earnings per share basis.

How many employees does Intra-Cellular Therapies have?

The company employs 512 workers across the globe.

How can I contact Intra-Cellular Therapies?

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The official website for the company is www.intracellulartherapies.com. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at ir@intracellulartherapies.com, or via fax at 646-440-9334.

This page (NASDAQ:ITCI) was last updated on 11/30/2022 by MarketBeat.com Staff